TY - JOUR
T1 - Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes
AU - Kupriyanova, Yuliya
AU - Yurchenko, Iryna
AU - Bobrov, Pavel
AU - Bartels, Frederik
AU - Wierichs, Stefan
AU - Jonuscheit, Marc
AU - Korzekwa, Benedict
AU - Prystupa, Katsiaryna
AU - Schön, Martin
AU - Mendez, Dania
AU - Trenkamp, Sandra
AU - Burkart, Volker
AU - Wagner, Robert
AU - Schrauwen-Hinderling, Vera
AU - Roden, Michael
AU - Roden, M.
AU - Al-Hasani, H.
AU - Belgardt, B.
AU - Bönhof, G.
AU - Geerling, G.
AU - Herder, C.
AU - Icks, A.
AU - Jandeleit-Dahm, K.
AU - Kotzka, J.
AU - Kuß, O.
AU - Lammert, E.
AU - Rathmann, W.
AU - Schlesinger, S.
AU - Schrauwen-Hinderling, V.
AU - Szendroedi, J.
AU - Trenkamp, S.
AU - Wagner, R.
AU - The German Diabetes Study (GDS) Group
N1 - Publisher Copyright:
© 2025 BMJ Publishing Group. All rights reserved.
PY - 2025
Y1 - 2025
N2 - Introduction The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes. Research design and methods Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58±12 years, body mass index 30.9±5.2kg/m2) were examined before (baseline) and 1 year (12±2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61±6 years, 30.0±4.6kg/m2). Results COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed. Conclusions History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.
AB - Introduction The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes. Research design and methods Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58±12 years, body mass index 30.9±5.2kg/m2) were examined before (baseline) and 1 year (12±2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61±6 years, 30.0±4.6kg/m2). Results COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0.04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed. Conclusions History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection.
UR - https://www.scopus.com/pages/publications/85219092494
U2 - 10.1136/bmjdrc-2024-004727
DO - 10.1136/bmjdrc-2024-004727
M3 - Article
C2 - 39965871
AN - SCOPUS:85219092494
SN - 2052-4897
VL - 13
JO - BMJ Open Diabetes Research and Care
JF - BMJ Open Diabetes Research and Care
IS - 1
M1 - e004727
ER -